Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction

BACKGROUND The assessment of myocardial viability has been used to identify patients with coronary artery disease and left ventricular dysfunction in whom coronary-artery bypass grafting (CABG) will provide a survival benefit. However, the efficacy of this approach is uncertain. METHODS In a substudy of patients with coronary artery disease and left ventricular dysfunction who were enrolled in a randomized trial of medical therapy with or without CABG, we used single-photon-emission computed tomography (SPECT), dobutamine echocardiography, or both to assess myocardial viability on the basis of pre-specified thresholds. RESULTS Among the 1212 patients enrolled in the randomized trial, 601 underwent assessment of myocardial viability. Of these patients, we randomly assigned 298 to receive medical therapy plus CABG and 303 to receive medical therapy alone. A total of 178 of 487 patients with viable myocardium (37%) and 58 of 114 patients without viable myocardium (51%) died (hazard ratio for death among patients with viable myocardium, 0.64; 95% confidence interval [CI], 0.48 to 0.86; P = 0.003). However, after adjustment for other baseline variables, this association with mortality was not significant (P = 0.21). There was no significant interaction between viability status and treatment assignment with respect to mortality (P = 0.53). CONCLUSIONS The presence of viable myocardium was associated with a greater likelihood of survival in patients with coronary artery disease and left ventricular dysfunction, but this relationship was not significant after adjustment for other baseline variables. The assessment of myocardial viability did not identify patients with a differential survival benefit from CABG, as compared with medical therapy alone.

National Heart, Lung, and Blood Institute (NHLBI/NIH)[U01-HL-069009]

National Heart, Lung, and Blood Institute (NHLBI/NIH)[HL-069010]

National Heart, Lung, and Blood Institute (NHLBI/NIH)[HL-069011]

National Heart, Lung, and Blood Institute (NHLBI/NIH)[HL-069012]

National Heart, Lung, and Blood Institute (NHLBI/NIH)[HL-069012-03]

National Heart, Lung, and Blood Institute (NHLBI/NIH)[HL-069013]

National Heart, Lung, and Blood Institute (NHLBI/NIH)[HL-069015]

National Heart, Lung, and Blood Institute (NHLBI/NIH)[HL-070011]

National Heart, Lung, and Blood Institute (NHLBI/NIH)[HL-072683]

Sorin

Astellas Healthcare

Bracco

Lantheus Medical Imaging

Mitralign

RegeneRx

Novartis

Gilead

Boehringer Ingelheim Pharmaceuticals